Cytek Biosciences (CTKB) Financials

$2.45 -0.03 (-1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 +0.12 (+4.90%)

As of 05:58 PM Eastern

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-6.02	-12	2.58
Consolidated Net Income / (Loss)	-6.02	-12	2.48
Net Income / (Loss) Continuing Operations	-6.02	-12	2.48
Total Pre-Tax Income	-5.70	-16	1.26
Total Operating Income	-21	-28	-1.80
Total Gross Profit	111	109	101
Total Revenue	200	193	164
Operating Revenue	200	193	164
Total Cost of Revenue	89	84	63
Operating Cost of Revenue	89	84	63
Total Operating Expenses	132	137	103
Selling, General & Admin Expense	43	44	35
Marketing Expense	49	49	33
Research & Development Expense	39	44	35
Total Other Income / (Expense), net	15	12	3.06
Interest Expense	-5.24	2.07	2.57
Interest & Investment Income	5.12	6.41	4.62
Other Income / (Expense), net	4.46	7.79	1.02
Income Tax Expense	0.32	-3.56	-1.22
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-0.09
Weighted Average Basic Shares Outstanding	130.61M	135.28M	134.51M
Weighted Average Diluted Shares Outstanding	130.61M	135.28M	138.56M
Weighted Average Basic & Diluted Shares Outstanding	128.10M	130.82M	135.43M

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	9.64	0.94	-10	-6.17	5.50	-6.46	-4.39	-6.81	3.53	1.67
Consolidated Net Income / (Loss)	9.64	0.94	-10	-6.17	5.50	-6.46	-4.39	-6.81	3.72	1.63
Net Income / (Loss) Continuing Operations	9.64	0.94	-10	-6.17	5.50	-6.46	-4.39	-6.81	3.72	1.63
Total Pre-Tax Income	10	0.16	-7.19	-8.99	4.11	-4.19	-6.60	-9.04	4.11	1.85
Total Operating Income	2.99	-4.25	-8.53	-11	-0.14	-6.42	-9.13	-12	0.08	1.36
Total Gross Profit	34	29	25	23	33	27	28	21	29	27
Total Revenue	57	52	47	45	58	48	50	37	48	40
Operating Revenue	57	52	47	45	58	48	50	37	48	40
Total Cost of Revenue	24	22	21	22	25	21	22	16	19	14
Operating Cost of Revenue	24	22	21	22	25	21	22	16	19	14
Total Operating Expenses	31	33	34	34	33	34	37	33	29	26
Selling, General & Admin Expense	9.07	11	12	11	11	10	11	12	11	8.04
Marketing Expense	12	12	12	13	12	12	14	11	9.03	8.81
Research & Development Expense	9.72	9.88	10	9.80	11	11	12	9.97	9.75	8.65
Total Other Income / (Expense), net	7.34	4.41	1.34	1.74	4.25	2.24	2.53	3.12	4.03	0.49
Interest Expense	-5.93	0.12	0.13	0.44	0.39	0.60	0.41	0.67	0.69	0.65
Interest & Investment Income	0.91	1.43	1.42	1.36	1.45	1.62	1.20	2.14	2.63	1.58
Other Income / (Expense), net	0.49	3.09	0.06	0.82	3.19	1.21	1.74	1.65	2.09	-0.45
Income Tax Expense	0.68	-0.78	3.25	-2.82	-1.39	2.27	-2.21	-2.23	0.40	0.22
Weighted Average Basic Shares Outstanding	130.61M	131.00M	131.44M	130.92M	135.28M	136.17M	135.92M	135.49M	134.51M	134.71M
Weighted Average Diluted Shares Outstanding	130.61M	132.79M	131.44M	130.92M	135.28M	136.17M	135.92M	135.49M	138.56M	138.71M
Weighted Average Basic & Diluted Shares Outstanding	128.10M	128.81M	131.51M	131.27M	130.82M	135.55M	136.36M	135.67M	135.43M	134.85M

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-69	-132	-65
Net Cash From Operating Activities	25	5.28	-12
Net Cash From Continuing Operating Activities	25	7.48	-12
Net Income / (Loss) Continuing Operations	-6.02	-12	2.48
Consolidated Net Income / (Loss)	-6.02	-12	2.48
Depreciation Expense	7.21	6.05	2.49
Amortization Expense	-1.93	-	3.09
Non-Cash Adjustments To Reconcile Net Income	18	21	17
Changes in Operating Assets and Liabilities, net	8.03	-7.10	-38
Net Cash From Investing Activities	-83	-94	-56
Net Cash From Continuing Investing Activities	-83	-94	-56
Purchase of Property, Plant & Equipment	-3.53	-4.69	-9.75
Acquisitions	-0.68	-45	-0.12
Purchase of Investments	-274	-176	-46
Sale of Property, Plant & Equipment	0.29	0.00	0.00
Sale and/or Maturity of Investments	195	132	0.00
Net Cash From Financing Activities	-16	-42	5.51
Net Cash From Continuing Financing Activities	-16	-44	5.51
Repayment of Debt	-0.56	-0.57	-0.05
Repurchase of Common Equity	-22	-44	0.00
Issuance of Debt	4.18	0.00	2.98
Other Financing Activities, net	2.17	1.05	2.58
Effect of Exchange Rate Changes	4.53	-	-2.49
Cash Income Taxes Paid	3.83	5.31	10

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-64	-16	8.78	1.51	3.38	33	-0.85	-167	-42	-8.37
Net Cash From Operating Activities	2.00	13	6.20	3.96	9.51	-4.24	-2.85	2.86	6.19	-7.50
Net Cash From Continuing Operating Activities	2.00	13	6.20	3.96	12	-4.24	-3.44	3.45	6.19	-7.50
Net Income / (Loss) Continuing Operations	9.64	0.94	-10	-6.17	5.50	-6.46	-4.39	-6.81	3.72	1.63
Consolidated Net Income / (Loss)	9.64	0.94	-10	-6.17	5.50	-6.46	-4.39	-6.81	3.72	1.63
Depreciation Expense	1.85	1.85	1.81	1.70	1.63	1.77	1.65	1.00	0.76	0.07
Amortization Expense	-0.69	-0.29	-0.51	-0.44	-	-0.77	-	-	1.03	0.70
Non-Cash Adjustments To Reconcile Net Income	-3.62	7.46	7.23	7.02	2.13	6.49	7.56	4.50	3.14	5.90
Changes in Operating Assets and Liabilities, net	-5.18	3.26	8.11	1.85	-0.43	-5.27	-6.15	4.75	-2.46	-16
Net Cash From Investing Activities	-63	-16	2.02	-5.75	29	43	2.79	-169	-51	-1.15
Net Cash From Continuing Investing Activities	-63	-16	2.02	-5.75	29	43	2.69	-169	-51	-1.15
Purchase of Property, Plant & Equipment	-0.89	-1.01	-1.05	-0.57	-1.54	-1.33	-1.17	-0.64	-6.53	-1.11
Acquisitions	-0.48	0.01	-0.15	-0.06	-0.06	-0.06	-0.06	-45	-0.08	-0.04
Purchase of Investments	-107	-53	-37	-77	-23	-23	-6.08	-123	-44	-
Sale of Property, Plant & Equipment	0.19	0.02	-	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	45	38	40	72	54	68	10	0.00	-	-
Net Cash From Financing Activities	-3.64	-12	-1.71	1.61	-34	-8.27	0.22	0.00	3.85	0.16
Net Cash From Continuing Financing Activities	-3.64	-12	-1.71	1.61	-36	-8.27	0.22	0.00	3.85	0.16
Repayment of Debt	-0.14	-0.14	-0.14	-0.14	-0.14	-0.14	-0.14	-0.15	-0.05	-
Repurchase of Common Equity	-6.99	-12	-	-	-35	-8.43	-	-	-	-
Issuance of Debt	2.79	0.01	-0.00	1.39	-	-	-	0.00	-	-
Other Financing Activities, net	1.71	0.00	0.09	0.36	0.24	0.29	0.37	0.15	0.92	0.16
Effect of Exchange Rate Changes	1.52	-0.94	2.26	1.70	-	-	-	-	-1.00	0.13
Cash Income Taxes Paid	1.91	0.86	1.06	0.00	4.50	0.13	0.59	0.09	0.46	2.27

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	500	494	519
Total Current Assets	396	392	454
Cash & Equivalents	99	167	297
Restricted Cash	0.03	0.33	2.90
Short-Term Investments	179	95	45
Accounts Receivable	61	56	49
Inventories, net	44	61	48
Prepaid Expenses	14	13	13
Plant, Property, & Equipment, net	18	18	14
Total Noncurrent Assets	85	84	52
Goodwill	17	16	10
Intangible Assets	20	23	4.33
Noncurrent Deferred & Refundable Income Taxes	33	30	20
Other Noncurrent Operating Assets	15	14	17
Total Liabilities & Shareholders' Equity	500	494	519
Total Liabilities	104	101	94
Total Current Liabilities	68	56	49
Accounts Payable	5.53	3.03	4.81
Accrued Expenses	21	20	21
Current Deferred Revenue	25	23	13
Other Current Liabilities	15	10	10
Total Noncurrent Liabilities	36	45	45
Asset Retirement Reserve & Litigation Obligation	9.04	16	16
Noncurrent Deferred Revenue	16	15	13
Other Noncurrent Operating Liabilities	11	14	16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	396	393	426
Total Preferred & Common Equity	396	393	426
Total Common Equity	396	393	426
Common Stock	431	424	443
Retained Earnings	-35	-29	-17
Accumulated Other Comprehensive Income / (Loss)	0.02	-1.28	-0.70

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	491	484	492	519	525	525	499
Total Current Assets	390	384	389	422	425	426	444
Cash & Equivalents	162	178	169	164	132	129	342
Restricted Cash	0.03	0.03	0.35	0.00	0.00	2.92	0.00
Short-Term Investments	116	99	101	124	167	170	-
Accounts Receivable	53	45	50	55	50	43	40
Inventories, net	47	50	55	67	66	70	49
Prepaid Expenses	13	12	13	12	11	11	13
Plant, Property, & Equipment, net	19	18	18	17	16	16	7.84
Total Noncurrent Assets	83	82	85	80	85	83	48
Goodwill	16	16	16	16	19	19	10
Intangible Assets	20	21	22	24	24	25	4.49
Noncurrent Deferred & Refundable Income Taxes	31	30	33	24	26	23	14
Other Noncurrent Operating Assets	15	14	14	15	15	16	19
Total Liabilities & Shareholders' Equity	491	484	492	519	525	525	499
Total Liabilities	106	95	99	104	101	101	83
Total Current Liabilities	63	52	56	59	54	57	41
Accounts Payable	5.39	3.19	3.73	4.71	3.08	5.28	5.64
Accrued Expenses	21	15	18	21	20	20	17
Current Deferred Revenue	25	24	23	23	21	18	12
Other Current Liabilities	11	9.73	11	10	10	13	7.12
Total Noncurrent Liabilities	43	42	44	45	47	45	41
Asset Retirement Reserve & Litigation Obligation	17	17	17	16	16	16	15
Noncurrent Deferred Revenue	15	14	15	15	16	13	10
Other Noncurrent Operating Liabilities	11	11	12	14	15	16	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	385	389	393	416	424	423	417
Total Preferred & Common Equity	385	389	393	416	424	423	417
Total Common Equity	385	389	393	416	424	423	417
Common Stock	430	435	430	452	454	448	438
Retained Earnings	-45	-46	-35	-35	-28	-24	-21
Accumulated Other Comprehensive Income / (Loss)	0.10	-0.20	-1.55	-1.58	-1.76	-0.59	-0.53

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	3.85%	17.67%	28.20%
EBITDA Growth	23.01%	-391.97%	-45.94%
EBIT Growth	19.90%	-2,451.02%	-110.30%
NOPAT Growth	26.30%	-448.06%	-176.19%
Net Income Growth	50.44%	-589.05%	-17.94%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	380.57%	143.18%	-364.17%
Free Cash Flow Firm Growth	97.23%	-54.26%	-85.09%
Invested Capital Growth	-9.57%	59.91%	99.91%
Revenue Q/Q Growth	-0.38%	5.41%	25.87%
EBITDA Q/Q Growth	-13.62%	20.47%	123.01%
EBIT Q/Q Growth	2.54%	4.22%	96.90%
NOPAT Q/Q Growth	13.20%	-0.80%	78.56%
Net Income Q/Q Growth	40.74%	12.81%	203.54%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-22.85%	169.16%	5.74%
Free Cash Flow Firm Q/Q Growth	-157.34%	4.92%	0.00%
Invested Capital Q/Q Growth	9.47%	2.21%	8.68%
Profitability Metrics	-	-	-
Gross Margin	55.43%	56.69%	61.56%
EBITDA Margin	-5.38%	-7.25%	2.92%
Operating Margin	-10.24%	-14.43%	-1.10%
EBIT Margin	-8.01%	-10.39%	-0.48%
Profit (Net Income) Margin	-3.00%	-6.29%	1.51%
Tax Burden Percent	105.61%	77.33%	197.14%
Interest Burden Percent	35.49%	78.35%	-160.31%
Effective Tax Rate	0.00%	0.00%	-97.14%
Return on Invested Capital (ROIC)	-11.58%	-18.40%	-5.82%
ROIC Less NNEP Spread (ROIC-NNEP)	-14.67%	-20.82%	-7.52%
Return on Net Nonoperating Assets (RNNOA)	10.05%	15.44%	6.42%
Return on Equity (ROE)	-1.53%	-2.97%	0.60%
Cash Return on Invested Capital (CROIC)	-1.52%	-64.50%	-72.45%
Operating Return on Assets (OROA)	-3.23%	-3.96%	-0.16%
Return on Assets (ROA)	-1.21%	-2.40%	0.51%
Return on Common Equity (ROCE)	-1.53%	-2.97%	0.60%
Return on Equity Simple (ROE_SIMPLE)	-1.52%	-3.09%	0.58%
Net Operating Profit after Tax (NOPAT)	-14	-19	-3.56
NOPAT Margin	-7.17%	-10.10%	-2.17%
Net Nonoperating Expense Percent (NNEP)	3.09%	2.42%	1.70%
Return On Investment Capital (ROIC_SIMPLE)	-3.63%	-4.96%	-0.84%
Cost of Revenue to Revenue	44.57%	43.31%	38.44%
SG&A Expenses to Revenue	21.51%	22.78%	21.15%
R&D to Revenue	19.66%	22.87%	21.25%
Operating Expenses to Revenue	65.67%	71.12%	62.66%
Earnings before Interest and Taxes (EBIT)	-16	-20	-0.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-14	4.80
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.11	3.15	3.24
Price to Tangible Book Value (P/TBV)	2.33	3.49	3.35
Price to Revenue (P/Rev)	4.17	6.40	8.39
Price to Earnings (P/E)	0.00	0.00	534.49
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.19%
Enterprise Value to Invested Capital (EV/IC)	4.74	7.47	12.67
Enterprise Value to Revenue (EV/Rev)	2.78	5.04	6.30
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	215.35
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	21.99	184.33	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.69	-0.74	-0.85
Leverage Ratio	1.26	1.24	1.18
Compound Leverage Factor	0.45	0.97	-1.90
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.82	8.30	10.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.86	6.97	9.26
Quick Ratio	5.00	5.66	7.95
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-1.89	-68	-44
Operating Cash Flow to CapEx	784.03%	112.65%	-125.47%
Free Cash Flow to Firm to Interest Expense	0.00	-32.99	-17.21
Operating Cash Flow to Interest Expense	0.00	2.55	-4.75
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.29	-8.54
Efficiency Ratios	-	-	-
Asset Turnover	0.40	0.38	0.33
Accounts Receivable Turnover	3.44	3.68	4.17
Inventory Turnover	1.71	1.53	1.57
Fixed Asset Turnover	11.02	12.03	16.80
Accounts Payable Turnover	20.87	21.33	16.09
Days Sales Outstanding (DSO)	106.08	99.08	87.47
Days Inventory Outstanding (DIO)	214.00	238.05	232.46
Days Payable Outstanding (DPO)	17.49	17.11	22.69
Cash Conversion Cycle (CCC)	302.60	320.02	297.25
Capital & Investment Metrics	-	-	-
Invested Capital	118	130	81
Invested Capital Turnover	1.62	1.82	2.68
Increase / (Decrease) in Invested Capital	-12	49	41
Enterprise Value (EV)	558	973	1,033
Market Capitalization	836	1,236	1,377
Book Value per Share	$3.07	$2.90	$3.16
Tangible Book Value per Share	$2.79	$2.61	$3.05
Total Capital	396	393	426
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-278	-263	-344
Capital Expenditures (CapEx)	3.24	4.69	9.75
Debt-free, Cash-free Net Working Capital (DFCFNWC)	51	73	61
Debt-free Net Working Capital (DFNWC)	329	336	405
Net Working Capital (NWC)	329	336	405
Net Nonoperating Expense (NNE)	-8.35	-7.34	-6.04
Net Nonoperating Obligations (NNO)	-278	-263	-344
Total Depreciation and Amortization (D&A)	5.28	6.05	5.58
Debt-free, Cash-free Net Working Capital to Revenue	25.39%	37.87%	37.15%
Debt-free Net Working Capital to Revenue	164.02%	173.99%	246.88%
Net Working Capital to Revenue	164.02%	173.99%	246.88%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	130.61M	135.28M	134.51M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	130.61M	135.28M	138.56M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	128.10M	130.82M	135.43M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-19	-1.26
Normalized NOPAT Margin	-7.17%	-10.10%	-0.77%
Pre Tax Income Margin	-2.84%	-8.14%	0.77%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	-9.68	-0.31
NOPAT to Interest Expense	0.00	-9.41	-1.38
EBIT Less CapEx to Interest Expense	0.00	-11.95	-4.09
NOPAT Less CapEx to Interest Expense	0.00	-11.68	-5.17
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-358.99%	-363.44%	0.00%

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.30%	7.29%	-6.19%	20.96%	20.48%	18.59%	23.74%	5.77%	230.57%	17.75%
EBITDA Growth	-1.11%	109.63%	-24.97%	9.00%	18.35%	-349.94%	-1,502.93%	-654.08%	118.28%	-37.39%
EBIT Growth	13.67%	77.80%	-14.63%	5.70%	40.60%	-669.62%	-545.15%	-284.84%	109.73%	-63.46%
NOPAT Growth	1,632.15%	-466.55%	6.57%	11.74%	-339.81%	-475.96%	-924.35%	-415.99%	-99.87%	-39.71%
Net Income Growth	75.21%	114.58%	-137.78%	9.37%	48.01%	-497.05%	-525.07%	-215.43%	419.14%	14.51%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-79.01%	411.89%	317.68%	38.45%	53.59%	43.51%	69.81%	293.11%	13.67%	-746.34%
Free Cash Flow Firm Growth	131.15%	90.15%	110.63%	90.44%	-20.54%	-20.36%	-83.72%	-82.73%	0.00%	-93.80%
Invested Capital Growth	-9.57%	-15.57%	-10.74%	0.52%	59.91%	70.04%	104.69%	170.49%	99.91%	183.78%
Revenue Q/Q Growth	11.60%	10.47%	3.92%	-22.97%	21.32%	-3.41%	33.99%	-23.27%	19.42%	0.79%
EBITDA Q/Q Growth	1,042.12%	105.66%	17.13%	-284.54%	211.27%	26.56%	39.66%	-340.01%	134.99%	312.22%
EBIT Q/Q Growth	400.43%	86.34%	14.56%	-424.10%	158.67%	29.44%	29.71%	-583.22%	137.70%	179.91%
NOPAT Q/Q Growth	110.96%	-326.56%	20.56%	-4,027.33%	95.95%	29.66%	24.95%	-11,314.47%	-93.65%	291.65%
Net Income Q/Q Growth	924.65%	109.02%	-69.14%	-212.10%	185.24%	-47.13%	35.54%	-283.08%	128.66%	331.62%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-84.90%	113.10%	56.79%	-58.40%	324.39%	-48.74%	-199.72%	-53.85%	182.53%	20.51%
Free Cash Flow Firm Q/Q Growth	371.97%	-174.94%	192.00%	83.39%	14.04%	19.13%	17.19%	-109.38%	14.17%	-23.44%
Invested Capital Q/Q Growth	9.47%	-3.78%	-8.42%	-6.25%	2.21%	1.72%	3.12%	49.14%	8.68%	22.46%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.55%	56.32%	54.56%	51.30%	56.75%	56.62%	56.67%	56.72%	60.77%	66.36%
EBITDA Margin	8.07%	0.79%	-15.38%	-19.29%	8.05%	-8.78%	-11.55%	-25.64%	8.20%	4.17%
Operating Margin	5.20%	-8.25%	-18.29%	-23.93%	-0.23%	-13.38%	-18.37%	-32.79%	0.17%	3.36%
EBIT Margin	6.05%	-2.25%	-18.17%	-22.09%	5.25%	-10.86%	-14.87%	-28.34%	4.50%	2.26%
Profit (Net Income) Margin	16.78%	1.83%	-22.38%	-13.75%	9.45%	-13.45%	-8.83%	-18.35%	7.69%	4.02%
Tax Burden Percent	93.41%	599.36%	145.20%	68.60%	133.86%	154.27%	66.54%	75.30%	90.37%	87.89%
Interest Burden Percent	296.95%	-13.57%	84.86%	90.74%	134.43%	80.30%	89.28%	86.01%	189.15%	202.19%
Effective Tax Rate	6.59%	-499.36%	0.00%	0.00%	-33.86%	0.00%	0.00%	0.00%	9.63%	12.11%
Return on Invested Capital (ROIC)	7.84%	-84.60%	-21.34%	-27.60%	-0.57%	-16.93%	-24.20%	-45.79%	0.42%	7.59%
ROIC Less NNEP Spread (ROIC-NNEP)	5.30%	-93.94%	-19.79%	-28.07%	-2.44%	-16.31%	-24.82%	-46.31%	-0.61%	7.47%
Return on Net Nonoperating Assets (RNNOA)	-3.64%	66.36%	14.02%	19.69%	1.81%	12.34%	19.27%	37.03%	0.52%	-6.55%
Return on Equity (ROE)	4.20%	-18.25%	-7.32%	-7.91%	1.24%	-4.59%	-4.93%	-8.76%	0.94%	1.04%
Cash Return on Invested Capital (CROIC)	-1.52%	2.80%	-3.89%	-15.69%	-64.50%	-70.97%	-83.61%	-101.80%	-72.45%	0.00%
Operating Return on Assets (OROA)	2.44%	-0.89%	-7.12%	-8.73%	2.00%	-3.90%	-5.13%	-9.31%	1.50%	0.62%
Return on Assets (ROA)	6.77%	0.73%	-8.77%	-5.43%	3.60%	-4.84%	-3.05%	-6.03%	2.57%	1.10%
Return on Common Equity (ROCE)	4.20%	-18.25%	-7.32%	-7.91%	1.24%	-4.59%	-4.93%	-8.76%	0.94%	1.04%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-2.64%	-4.51%	-2.93%	0.00%	-3.35%	-1.38%	-0.51%	0.00%	-0.58%
Net Operating Profit after Tax (NOPAT)	2.79	-25	-5.97	-7.51	-0.18	-4.49	-6.39	-8.51	0.08	1.20
NOPAT Margin	4.85%	-49.44%	-12.80%	-16.75%	-0.31%	-9.36%	-12.86%	-22.95%	0.16%	2.95%
Net Nonoperating Expense Percent (NNEP)	2.54%	9.33%	-1.55%	0.47%	1.87%	-0.62%	0.62%	0.51%	1.03%	0.12%
Return On Investment Capital (ROIC_SIMPLE)	0.70%	-	-	-	-0.05%	-	-	-	0.02%	-
Cost of Revenue to Revenue	41.45%	43.68%	45.44%	48.70%	43.25%	43.38%	43.33%	43.28%	39.23%	33.64%
SG&A Expenses to Revenue	15.78%	21.25%	25.09%	25.43%	18.47%	21.56%	21.71%	32.57%	21.75%	19.87%
R&D to Revenue	16.92%	19.19%	21.45%	21.84%	18.67%	23.27%	24.42%	26.89%	20.17%	21.37%
Operating Expenses to Revenue	53.35%	64.57%	72.86%	75.23%	56.98%	70.00%	75.04%	89.52%	60.60%	63.00%
Earnings before Interest and Taxes (EBIT)	3.48	-1.16	-8.47	-9.91	3.06	-5.21	-7.39	-11	2.18	0.92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.64	0.41	-7.17	-8.65	4.69	-4.21	-5.74	-9.51	3.96	1.69
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.11	1.89	1.88	2.24	3.15	1.81	2.73	2.94	3.24	4.76
Price to Tangible Book Value (P/TBV)	2.33	2.09	2.08	2.48	3.49	2.01	3.04	3.28	3.35	4.93
Price to Revenue (P/Rev)	4.17	3.62	3.70	4.37	6.40	4.11	6.60	7.49	8.39	15.21
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	534.49	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.19%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.74	4.19	4.07	4.97	7.47	3.64	6.86	7.76	12.67	21.87
Enterprise Value to Revenue (EV/Rev)	2.78	2.24	2.30	3.03	5.04	2.54	4.90	5.68	6.30	12.59
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	215.35	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	21.99	13.70	29.50	95.20	184.33	236.84	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	136.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.69	-0.71	-0.71	-0.70	-0.74	-0.76	-0.78	-0.80	-0.85	-0.88
Leverage Ratio	1.26	1.26	1.24	1.25	1.24	1.22	1.22	1.22	1.18	1.16
Compound Leverage Factor	3.74	-0.17	1.05	1.13	1.67	0.98	1.09	1.05	2.24	2.35
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.95	5.21	5.69	6.35	8.46	5.41	7.95	8.42	10.01	15.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.86	6.21	7.33	6.99	6.97	7.20	7.93	7.53	9.26	10.70
Quick Ratio	5.00	5.26	6.14	5.77	5.66	5.85	6.50	6.05	7.95	9.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	15	-5.61	7.49	-8.14	-49	-57	-70	-85	-41	-47
Operating Cash Flow to CapEx	284.07%	1,335.45%	589.17%	697.88%	617.66%	-318.72%	-242.76%	443.79%	94.84%	-676.04%
Free Cash Flow to Firm to Interest Expense	0.00	-47.17	55.90	-18.46	-124.38	-95.82	-172.36	-126.49	-59.18	-72.98
Operating Cash Flow to Interest Expense	0.00	111.10	46.30	8.97	24.14	-7.12	-6.97	4.25	9.01	-11.56
Operating Cash Flow Less CapEx to Interest Expense	0.00	102.78	38.44	7.69	20.23	-9.36	-9.84	3.29	-0.49	-13.27
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.40	0.39	0.40	0.38	0.36	0.35	0.33	0.33	0.27
Accounts Receivable Turnover	3.44	3.72	4.19	4.30	3.68	3.85	4.06	4.52	4.17	3.77
Inventory Turnover	1.71	1.60	1.54	1.44	1.53	1.33	1.26	1.20	1.57	1.49
Fixed Asset Turnover	11.02	11.20	11.73	11.88	12.03	14.50	15.32	15.06	16.80	20.32
Accounts Payable Turnover	20.87	17.96	28.39	19.85	21.33	14.95	14.27	11.42	16.09	11.93
Days Sales Outstanding (DSO)	106.08	97.99	87.01	84.90	99.08	94.72	89.83	80.78	87.47	96.75
Days Inventory Outstanding (DIO)	214.00	228.71	237.36	253.67	238.05	274.21	288.94	305.42	232.46	245.80
Days Payable Outstanding (DPO)	17.49	20.32	12.86	18.39	17.11	24.42	25.57	31.97	22.69	30.59
Cash Conversion Cycle (CCC)	302.60	306.38	311.52	320.18	320.02	344.51	353.20	354.24	297.25	311.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	118	108	112	122	130	128	125	122	81	75
Invested Capital Turnover	1.62	1.71	1.67	1.65	1.82	1.81	1.88	1.99	2.68	2.57
Increase / (Decrease) in Invested Capital	-12	-20	-13	0.63	49	53	64	77	41	49
Enterprise Value (EV)	558	451	455	607	973	465	860	943	1,033	1,640
Market Capitalization	836	729	733	878	1,236	753	1,159	1,245	1,377	1,982
Book Value per Share	$3.07	$2.93	$2.96	$3.00	$2.90	$3.05	$3.13	$3.13	$3.16	$3.09
Tangible Book Value per Share	$2.79	$2.65	$2.68	$2.71	$2.61	$2.75	$2.81	$2.80	$3.05	$2.99
Total Capital	396	385	389	393	393	416	424	423	426	417
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-278	-278	-277	-270	-263	-288	-299	-302	-344	-342
Capital Expenditures (CapEx)	0.70	0.99	1.05	0.57	1.54	1.33	1.17	0.64	6.53	1.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	51	50	54	63	73	76	72	67	61	61
Debt-free Net Working Capital (DFNWC)	329	327	332	333	336	364	371	369	405	402
Net Working Capital (NWC)	329	327	332	333	336	364	371	369	405	402
Net Nonoperating Expense (NNE)	-6.85	-26	4.47	-1.34	-5.69	1.96	-2.00	-1.71	-3.64	-0.43
Net Nonoperating Obligations (NNO)	-278	-278	-277	-270	-263	-288	-299	-302	-344	-342
Total Depreciation and Amortization (D&A)	1.16	1.56	1.30	1.26	1.63	1.00	1.65	1.00	1.79	0.77
Debt-free, Cash-free Net Working Capital to Revenue	25.39%	24.64%	27.55%	31.20%	37.87%	41.29%	41.23%	40.46%	37.15%	46.69%
Debt-free Net Working Capital to Revenue	164.02%	162.71%	167.77%	165.89%	173.99%	198.57%	211.41%	222.27%	246.88%	308.75%
Net Working Capital to Revenue	164.02%	162.71%	167.77%	165.89%	173.99%	198.57%	211.41%	222.27%	246.88%	308.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	130.61M	131.00M	131.44M	130.92M	135.28M	136.17M	135.92M	135.49M	134.51M	134.71M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	130.61M	132.79M	131.44M	130.92M	135.28M	136.17M	135.92M	135.49M	138.56M	138.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	128.10M	128.81M	131.51M	131.27M	130.82M	135.55M	136.36M	135.67M	135.43M	134.85M
Normalized Net Operating Profit after Tax (NOPAT)	2.79	-2.97	-5.97	-7.51	-0.10	-4.49	-6.39	-8.51	0.08	1.20
Normalized NOPAT Margin	4.85%	-5.77%	-12.80%	-16.75%	-0.16%	-9.36%	-12.86%	-22.95%	0.16%	2.95%
Pre Tax Income Margin	17.96%	0.30%	-15.42%	-20.05%	7.06%	-8.72%	-13.27%	-24.37%	8.51%	4.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-9.72	-63.19	-22.47	7.76	-8.76	-18.06	-15.62	3.17	1.41
NOPAT to Interest Expense	0.00	-213.96	-44.54	-17.04	-0.46	-7.55	-15.62	-12.65	0.11	1.84
EBIT Less CapEx to Interest Expense	0.00	-18.04	-71.05	-23.76	3.85	-11.00	-20.93	-16.57	-6.34	-0.30
NOPAT Less CapEx to Interest Expense	0.00	-222.28	-52.40	-18.32	-4.37	-9.79	-18.49	-13.61	-9.39	0.13
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-358.99%	-485.89%	-261.11%	0.00%	-363.44%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Cytek Biosciences' Financials

When does Cytek Biosciences's fiscal year end?

According to the most recent income statement we have on file, Cytek Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cytek Biosciences' net income changed over the last 2 years?

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$6.02 million in 2024, falling from $2.48 million in 2022. The previous period was -$12.15 million in 2023. View Cytek Biosciences' forecast to see where analysts expect Cytek Biosciences to go next.

What is Cytek Biosciences's operating income?

Cytek Biosciences's total operating income in 2024 was -$20.52 million, based on the following breakdown:

Total Gross Profit: $111.11 million
Total Operating Expenses: $131.63 million

How has Cytek Biosciences revenue changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' total revenue changed from $164.04 million in 2022 to $200.45 million in 2024, a change of 22.2%.

How much debt does Cytek Biosciences have?

Cytek Biosciences' total liabilities were at $103.76 million at the end of 2024, a 2.3% increase from 2023, and a 10.5% increase since 2022.

How much cash does Cytek Biosciences have?

In the past 2 years, Cytek Biosciences' cash and equivalents has ranged from $98.72 million in 2024 to $296.60 million in 2022, and is currently $98.72 million as of their latest financial filing in 2024.

How has Cytek Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' book value per share changed from 3.16 in 2022 to 3.07 in 2024, a change of -2.6%.

Related Companies

This page (NASDAQ:CTKB) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Financials

Frequently Asked Questions About Cytek Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Financials

Annual Income Statements for Cytek Biosciences

Quarterly Income Statements for Cytek Biosciences

Annual Cash Flow Statements for Cytek Biosciences

Quarterly Cash Flow Statements for Cytek Biosciences

Annual Balance Sheets for Cytek Biosciences

Quarterly Balance Sheets for Cytek Biosciences

Annual Metrics And Ratios for Cytek Biosciences

Quarterly Metrics And Ratios for Cytek Biosciences

Frequently Asked Questions About Cytek Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools